加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.16
+US$0.03 · +2.65%
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
常规交易时段
US$1.16
+US$0.03 · +2.65%
盘中时间采用ET。市场数据可能有所延迟。
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
日内区间
当前US$1.16
52周区间
当前US$1.16
盘中时间采用ET。市场数据可能有所延迟。
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
日内区间
当前US$1.16
52周区间
当前US$1.16
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 270.74万 USD | 363.34万 USD | 29.92万 USD | 29.24万 USD | 8831 USD |
| 销货成本 | 481.03万 USD | 359.41万 USD | — | — | — |
| 毛利 | −210.29万 USD | 3.93万 USD | 29.92万 USD | 29.24万 USD | 8831 USD |
| 研究与开发 | — | 2751.52万 USD | 1755.94万 USD | 1380.04万 USD | 412.48万 USD |
| 销售、一般及管理费用 | 1586.14万 USD | 1652.6万 USD | 1521.82万 USD | 1302.1万 USD | 1084.79万 USD |
| 营业费用 | 6473.25万 USD | 3821.31万 USD | 3692.01万 USD | 3480.04万 USD | 1992.52万 USD |
| 利息收入 | — | 88.82万 USD | 5.05万 USD | 14.5万 USD | — |
| 利息支出 | 10.99万 USD | 6.53万 USD | 64.29万 USD | 8.61万 USD | 934.97万 USD |
| 折旧和摊销 | 274.7万 USD | 270.16万 USD | 300.26万 USD | 324.58万 USD | 298.29万 USD |
| 营业利润 | −6683.54万 USD | −3817.39万 USD | −3662.09万 USD | −3450.81万 USD | −1991.64万 USD |
| 净利润 | −5394.41万 USD | −3834.25万 USD | −4794.91万 USD | −3461.12万 USD | −3033.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
